Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells

Stem Cell Reports

Volumn 4, Issue 5, 2015, Pages 899-913

  Cheng, Peng ^a,e   Phillips, Emma ^b   Kim, Sung Hak ^a   Taylor, David ^a   Hielscher, Thomas ^b   Puccio, Laura ^b   Hjelmeland, Anita B ^c   Lichter, Peter ^b   Nakano, Ichiro ^a,d   Goidts, Violaine ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KINOME; PROTEIN AXL; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; HERMES ANTIGEN; ONCOPROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXL GENE; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; GENE; GENE EXPRESSION; GENE SILENCING; GENOMICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN TUMOR; CANCER STAGING; CANCER STEM CELL; CYTOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL CULTURE; UPREGULATION; XENOGRAFT;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; BRAIN NEOPLASMS; CARCINOGENESIS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84929294413     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2015.03.005     Document Type: Article

References (47)

1. K.P. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink, F. Hollingsworth, K. Wani, L. Heathcock, J.D. James, and L.D. Goodman Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma Cancer Cell 24 2013 331 346
2. C.W. Brennan, R.G. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S.R. Salama, S. Zheng, D. Chakravarty, J.Z. Sanborn, S.H. Berman TCGA Research Network The somatic genomic landscape of glioblastoma Cell 155 2013 462 477
3. O. Celiku, S. Johnson, S. Zhao, K. Camphausen, and U. Shankavaram Visualizing molecular profiles of glioblastoma with GBM-BioDP PLoS ONE 9 2014 e101239
4. T.K. Choueiri, U. Vaishampayan, J.E. Rosenberg, T.F. Logan, A.L. Harzstark, R.M. Bukowski, B.I. Rini, S. Srinivas, M.N. Stein, and L.M. Adams Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma J. Clin. Oncol. 31 2013 181 186
5. E.A. Collisson, A. Sadanandam, P. Olson, W.J. Gibb, M. Truitt, S. Gu, J. Cooc, J. Weinkle, G.E. Kim, and L. Jakkula Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat. Med. 17 2011 500 503
6. F. De Bacco, E. Casanova, E. Medico, S. Pellegatta, F. Orzan, R. Albano, P. Luraghi, G. Reato, A. D'Ambrosio, and P. Porrati The MET oncogene is a functional marker of a glioblastoma stem cell subtype Cancer Res. 72 2012 4537 4550
7. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, J.M. Ford, R. Capdeville, and M. Talpaz Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042
8. A. Ernst, S. Hofmann, R. Ahmadi, N. Becker, A. Korshunov, F. Engel, C. Hartmann, J. Felsberg, M. Sabel, and H. Peterziel Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival Clin. Cancer Res. 15 2009 6541 6550
9. V. Goidts, J. Bageritz, L. Puccio, S. Nakata, M. Zapatka, S. Barbus, G. Toedt, B. Campos, A. Korshunov, and S. Momma RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival Oncogene 31 2012 3235 3243
10. L.A. Gravendeel, M.C. Kouwenhoven, O. Gevaert, J.J. de Rooi, A.P. Stubbs, J.E. Duijm, A. Daemen, F.E. Bleeker, L.B. Bralten, and N.K. Kloosterhof Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res. 69 2009 9065 9072
11. C. Gu, Y.K. Banasavadi-Siddegowda, K. Joshi, Y. Nakamura, H. Kurt, S. Gupta, and I. Nakano Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner Stem Cells 31 2013 870 881
12. H. Guvenc, M.S. Pavlyukov, K. Joshi, H. Kurt, Y.K. Banasavadi-Siddegowda, P. Mao, C. Hong, R. Yamada, C.H. Kwon, and D. Bhasin Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex Clin. Cancer Res. 19 2013 631 642
13. H.D. Hemmati, I. Nakano, J.A. Lazareff, M. Masterman-Smith, D.H. Geschwind, M. Bronner-Fraser, and H.I. Kornblum Cancerous stem cells can arise from pediatric brain tumors Proc. Natl. Acad. Sci. USA 100 2003 15178 15183
14. S.J. Holland, A. Pan, C. Franci, Y. Hu, B. Chang, W. Li, M. Duan, A. Torneros, J. Yu, and T.J. Heckrodt R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer Cancer Res. 70 2010 1544 1554
15. M. Hummel, S. Bentink, H. Berger, W. Klapper, S. Wessendorf, T.F. Barth, H.W. Bernd, S.B. Cogliatti, J. Dierlamm, A.C. Feller Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling N. Engl. J. Med. 354 2006 2419 2430
16. M. Janning, I. Ben-Batalla, and S. Loges Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Rev Hematol 8 2015 135 138
17. M. Jijiwa, H. Demir, S. Gupta, C. Leung, K. Joshi, N. Orozco, T. Huang, V.O. Yildiz, I. Shibahara, and J.A. de Jesus CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway PLoS ONE 6 2011 e24217
18. A.K. Keating, G.K. Kim, A.E. Jones, A.M. Donson, K. Ware, J.M. Mulcahy, D.B. Salzberg, N.K. Foreman, X. Liang, A. Thorburn, and D.K. Graham Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity Mol. Cancer Ther. 9 2010 1298 1307
19. K.H. Knubel, B.M. Pernu, A. Sufit, S. Nelson, A.M. Pierce, and A.K. Keating MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme Oncotarget 5 2014 1338 1351
20. J. Lee, S. Kotliarova, Y. Kotliarov, A. Li, Q. Su, N.M. Donin, S. Pastorino, B.W. Purow, N. Christopher, and W. Zhang Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 2006 391 403
21. R.M. Linger, A.K. Keating, H.S. Earp, and D.K. Graham TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer Adv. Cancer Res. 100 2008 35 83
22. L. Liu, J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan, W. Halsey, G.M. Sathe, A.M. Martin, and T.M. Gilmer Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL Cancer Res. 69 2009 6871 6878
23. P. Mao, K. Joshi, J. Li, S.H. Kim, P. Li, L. Santana-Santos, S. Luthra, U.R. Chandran, P.V. Benos, and L. Smith Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3 Proc. Natl. Acad. Sci. USA 110 2013 8644 8649
24. I.K. Mellinghoff, N. Schultz, P.S. Mischel, and T.F. Cloughesy Will kinase inhibitors make it as glioblastoma drugs? Curr. Top. Microbiol. Immunol. 355 2012 135 169
25. T. Miyazaki, Y. Pan, K. Joshi, D. Purohit, B. Hu, H. Demir, S. Mazumder, S. Okabe, T. Yamori, and M. Viapiano Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb Clin. Cancer Res. 18 2012 1268 1280
26. I. Nakano, and H.I. Kornblum Methods for analysis of brain tumor stem cell and neural stem cell self-renewal Methods Mol. Biol. 568 2009 37 56
27. I. Nakano, K. Joshi, K. Visnyei, B. Hu, M. Watanabe, D. Lam, E. Wexler, K. Saigusa, Y. Nakamura, and D.R. Laks Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway Neuro-oncol. 13 2011 622 634
28. J.P. O'Bryan, R.A. Frye, P.C. Cogswell, A. Neubauer, B. Kitch, C. Prokop, R. Espinosa 3rd, M.M. Le Beau, H.S. Earp, and E.T. Liu axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase Mol. Cell. Biol. 11 1991 5016 5031
29. A.P. Patel, I. Tirosh, J.J. Trombetta, A.K. Shalek, S.M. Gillespie, H. Wakimoto, D.P. Cahill, B.V. Nahed, W.T. Curry, and R.L. Martuza Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma Science 344 2014 1396 1401
30. H.S. Phillips, S. Kharbanda, R. Chen, W.F. Forrest, R.H. Soriano, T.D. Wu, A. Misra, J.M. Nigro, H. Colman, and L. Soroceanu Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173
31. Y. Piao, J. Liang, L. Holmes, V. Henry, E. Sulman, and J.F. de Groot Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition Clin. Cancer Res. 19 2013 4392 4403
32. F. Qian, S. Engst, K. Yamaguchi, P. Yu, K.A. Won, L. Mock, T. Lou, J. Tan, C. Li, and D. Tam Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 69 2009 8009 8016
33. RDC Team R: A Language and Environment for Statistical Computing 2011 R Foundation for Statistical Computing Vienna
34. M.A. Shah, Z.A. Wainberg, D.V. Catenacci, H.S. Hochster, J. Ford, P. Kunz, F.C. Lee, H. Kallender, F. Cecchi, and D.C. Rabe Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer PLoS ONE 8 2013 e54014
35. S.K. Singh, C. Hawkins, I.D. Clarke, J.A. Squire, J. Bayani, T. Hide, R.M. Henkelman, M.D. Cusimano, and P.B. Dirks Identification of human brain tumour initiating cells Nature 432 2004 396 401
36. J.J. Smith, N.G. Deane, F. Wu, N.B. Merchant, B. Zhang, A. Jiang, P. Lu, J.C. Johnson, C. Schmidt, and C.E. Bailey Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer Gastroenterology 138 2010 958 968
37. G.K. Smyth Linear models and empirical bayes methods for assessing differential expression in microarray experiments Stat. Appl. Genet. Mol. Biol. 3 2004 e3
38. G.K. Smyth Limma: Linear Models for Microarray Data 2005 Springer New York
39. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
40. D. Sturm, H. Witt, V. Hovestadt, D.A. Khuong-Quang, D.T. Jones, C. Konermann, E. Pfaff, M. Tönjes, M. Sill, and S. Bender Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma Cancer Cell 22 2012 425 437
41. L. Sun, A.M. Hui, Q. Su, A. Vortmeyer, Y. Kotliarov, S. Pastorino, A. Passaniti, J. Menon, J. Walling, and R. Bailey Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain Cancer Cell 9 2006 287 300
42. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, S. Lade, D.S. Johnson, M.K. Trivett, D. Etemadmoghadam, B. Locandro Australian Ovarian Cancer Study Group Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin. Cancer Res. 14 2008 5198 5208
43. P. Vajkoczy, P. Knyazev, A. Kunkel, H.H. Capelle, S. Behrndt, H. von Tengg-Kobligk, F. Kiessling, U. Eichelsbacher, M. Essig, and T.A. Read Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival Proc. Natl. Acad. Sci. USA 103 2006 5799 5804
44. R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, M.D. Wilkerson, C.R. Miller, L. Ding, T. Golub, J.P. Mesirov Cancer Genome Atlas Research Network Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
45. K. Vuoriluoto, H. Haugen, S. Kiviluoto, J.P. Mpindi, J. Nevo, C. Gjerdrum, C. Tiron, J.B. Lorens, and J. Ivaska Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer Oncogene 30 2011 1436 1448
46. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
47. Z. Zhang, J.C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A.D. Levine, and J.K. Rho Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat. Genet. 44 2012 852 860